Tuberculosis is the most common infectious disease worldwide. In 2022 alone, there were 10.6 million new infections and 1.3 million deaths. The European-African network PanACEA—a consortium of
The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses.The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)
Microorganisms produce a wide variety of natural products that can be used as active agents to treat diseases such as infections or cancer. The blueprints for these molecules can be found in the
On the occasion of World AIDS Day on 1 December 2024, the International Antiviral (formerly AIDS) Society-USA (IAS-USA) has published new international guidelines for the treatment and prevention of
The development of an effective vaccine against the hepatitis C virus has been an enormous challenge for decades due to the high genetic diversity of the virus. The research team led by DZIF scientist
Antibacterial drugs are important for treating infections. However, increasing bacterial resistance to current drugs—making them ineffective or only partially effective—means that new drugs are
DZIF scientist Michael Ramharter from the Bernhard Nocht Institute for Tropical Medicine in Hamburg and the University Medical Center Hamburg-Eppendorf has received the Memento Research Prize 2024
Antimicrobial resistance (AMR) is one of the most urgent challenges facing global health and development. Described as a “creeping pandemic” by the G7 forum of leading economic nations, AMR occurs
Professors Ivo Boneca (Institut Pasteur, Paris), Mark Brönstrup (Helmholtz Centre for Infection Research, Braunschweig, and German Center for Infection Research), and Christophe Zimmer (University of
